This HTML5 document contains 93 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbpedia-shhttp://sh.dbpedia.org/resource/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n21https://global.dbpedia.org/id/
umbel-rchttp://umbel.org/umbel/rc/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n16http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
dbpedia-srhttp://sr.dbpedia.org/resource/
n20http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:List_of_dopaminergic_drugs
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:David_E._Nichols
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Dopamine_agonist
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Dopamine_receptor_D1
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Dopamine_receptor_D2
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Dopamine_receptor_D5
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Dopaminergic
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Benzhydryl_compounds
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
dbr:Dihydrexidine
rdf:type
owl:Thing yago:Matter100020827 yago:WikicatBiasedLigands yago:PhysicalEntity100001930 dbo:ChemicalSubstance n16:ChemicalObject dbo:Drug wikidata:Q8386 yago:Substance100020090 umbel-rc:DrugProduct yago:Ligand115110307
rdfs:label
Dihydrexidine
rdfs:comment
Dihydrexidine (DAR-0100) is a moderately selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Although dihydrexidine has some affinity for the D2 receptor, it has functionally selective (highly biased) D2 signaling, thereby explaining why it lacks D2 agonist behavioral qualities. There have been several reviews of relevance to the compound.
foaf:depiction
n20:Dihydrexidine_structure.png
dcterms:subject
dbc:D5_receptor_agonists dbc:D1-receptor_agonists dbc:Catechols dbc:D2-receptor_agonists dbc:Biased_ligands
dbo:wikiPageID
3829067
dbo:wikiPageRevisionID
1051573529
dbo:wikiPageWikiLink
dbc:D5_receptor_agonists dbr:D5_receptor dbr:Hypotension dbr:D2_receptor dbr:D1_receptor dbr:Binding_selectivity dbc:D1-receptor_agonists dbr:Therapy dbr:Drug_development dbc:Catechols dbr:Schizophrenia dbc:Biased_ligands dbc:D2-receptor_agonists dbr:Dopamine dbr:Full_agonist dbr:Clinical_trial dbr:Cognitive_deficit dbr:Memory_deficit dbr:Parkinson's_disease
owl:sameAs
dbpedia-sh:Dihidreksidin yago-res:Dihydrexidine dbpedia-sr:Dihidreksidin freebase:m.0b2396 wikidata:Q5276413 n21:4iuLL
dbp:wikiPageUsesTemplate
dbt:Drugbox dbt:Ebicite dbt:Dopamine_receptor_modulators dbt:Fdacite dbt:Stimulants dbt:Chemspidercite dbt:Cascite dbt:Stdinchicite dbt:Reflist dbt:Antihypertensive-stub dbt:Antihypertensives
dbo:thumbnail
n20:Dihydrexidine_structure.png?width=300
dbp:atcPrefix
none
dbp:c
17
dbp:casNumber
123039
dbp:chembl
25856
dbp:chemspiderid
5036130
dbp:h
17
dbp:iupacName
566
dbp:n
1
dbp:o
2
dbp:pubchem
5311070
dbp:smiles
c1ccc2cCN[C@H]3[C@H]2c4ccO
dbp:stdinchi
1
dbp:stdinchikey
BGOQGUHWXBGXJW-RHSMWYFYSA-N
dbp:unii
32
dbp:verifiedfields
changed
dbp:verifiedrevid
414782444
dbp:watchedfields
changed
dbo:abstract
Dihydrexidine (DAR-0100) is a moderately selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Although dihydrexidine has some affinity for the D2 receptor, it has functionally selective (highly biased) D2 signaling, thereby explaining why it lacks D2 agonist behavioral qualities. Dihydrexidine has shown impressive antiparkinson effects in the MPTP-primate model, and has been investigated for the treatment of Parkinson's disease. In an early clinical trial the drug was given intravenously and led to profound hypotension so development was halted. The drug was resurrected when it was shown that smaller subcutaneous doses were safe. This led to a pilot study in schizophrenia and current clinical trials to assess its efficacy in improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder. There have been several reviews of relevance to the compound.
prov:wasDerivedFrom
wikipedia-en:Dihydrexidine?oldid=1051573529&ns=0
dbo:wikiPageLength
7098
dbo:casNumber
123039-93-0
dbo:chEMBL
25856
dbo:fdaUniiCode
32D64VH037
dbo:pubchem
5311070
foaf:isPrimaryTopicOf
wikipedia-en:Dihydrexidine
Subject Item
dbr:C17H17NO2
dbo:wikiPageWikiLink
dbr:Dihydrexidine
Subject Item
wikipedia-en:Dihydrexidine
foaf:primaryTopic
dbr:Dihydrexidine